Health Trials

About this trial

The current proposal is aimed to confirm the efficacy of this novel therapeutic method (autonomous eye movement desensitization and reprocessing; A-EMDR) in a patient group (PTSD and SUD), and to assess the feasibility of the application within this group. While there is no basis to assume lower efficacy of the treatment with this population, confirming that hypothesis is an important and helpful step before a full-performance research study can be initiated. Furthermore, this study proposal will provide additional information regarding the feasibility for this population, which will allow for a more tailored approach in future study.

Eligibility criteria

Qualifiers

Aged 18-years old or older

Fluent in English

Diagnosed with PTSD by the PTSD Checklist for DSM-5 (PCL-5 past month version score >32)

Diagnosed with past-year substance use disorder other than caffeine by structured clinical interview for DSM-5 (SCID-5)

Disqualifiers

Diagnosis of a severe or unstable mental illness that precludes safe participation in the study by a healthcare practitioner such as acute psychosis or mania diagnosed by a healthcare practitioner

Current suicidality risk as indicated during the conduct of the Columbia Suicide Severity Rating Scale (C-SSRS) (21) with concurrence after a study physician's evaluation if the response to C-SSRS questions 1 or 2 is "yes"

Trial design

Treatments tested in this trial

  • A-EMDR
  • Treatment as Usual (TAU)

Treatment groups

24 Participants
are divided into 2 treatment groups

Locations

1
100 Stokes St TorontoOntario, Canada

Sponsors and collaborators

Centre for Addiction and Mental Health

Lead sponsor

Source ClinicalTrials.gov